@article {Abolhasani:2020:1872-3136:38,
title = "Cytotoxicity Evaluation of Dimethoxy and Trimethoxy Indanonic Spiroisoxazolines Against Cancerous Liver Cells",
journal = "Current Chemical Biology",
parent_itemid = "infobike://ben/ccb",
publishercode ="ben",
year = "2020",
volume = "14",
number = "1",
publication date ="2020-03-01T00:00:00",
pages = "38-47",
itemtype = "ARTICLE",
issn = "1872-3136",
url = "https://www.ingentaconnect.com/content/ben/ccb/2020/00000014/00000001/art00007",
doi = "doi:10.2174/2212796813666190926112807",
keyword = "cancerous
liver cells, antitubulin, indanonic spiroisoxazoline, HepG2, selective COX-2 inhibitor, Anticancer",
author = "Abolhasani, Ahmad and Heidari, Fatemeh and Noori, Somayeh and Mousavi, Shokoufeh and Abolhasani, Hoda",
abstract = "Background: 3'-(3,4-dimethoxyphenyl)-4'-(4-(methylsulfonyl)phenyl)-4'H-spiro [indene-2,5'-isoxazol]-1(3H)-one and 4'-(4-(methylsulfonyl)phenyl)-3'-(3,4,5-trimethoxyphenyl)- 4'H-spiro[indene-2,5'-isoxazol]-1(3H)-one compounds containing indanonic spiroisoxazoline core are widely known
for their antiproliferative activities and investigation of tubulin binding modes. Objective: To evaluate the cytotoxicity effect of Dimethoxy and Trimethoxy Indanonic Spiroisoxazolines against HepG2 cancerous liver cell line and to perform a comparison with other known anti-liver cancer
drugs. Methods: The evaluation of cytotoxicity of dimethoxy and trimethoxy indanonic spiroisoxazoline compounds, Oxaliplatin, Doxorubicin, 5-fluorouracil and Cisplatin against HepG2 (hepatocellular liver carcinoma) cell line has been performed using MTT assay and analyzed by GraphPad
PRISM software (version 8.0.2). Results: Potent cytotoxicity effects against HepG2 cell line, comparable to Cisplatin (IC50= 0.047\textpm0.0045 M), Oxaliplatin (IC50= 0.0051M), Doxorubicin (IC50= 0.0014M) and 5- fluorouracil (IC50= 0.0089 M), were shown by both dimethoxy
(IC50= 0.059\textpm0.012 M) and trimethoxy (IC50= 0.086\textpm0.019 M) indanonic spiroisoxazoline compounds. Conclusion: In vitro biological evaluations revealed that dimethoxy and trimethoxy indanonic spiroisoxazoline compounds are good candidates for the development of new
anti-liver cancer agents.",
}